Clinical trials: Oral Neoplasm, active
Salivary Gland Neoplasms
A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma
The purpose of the study is to evaluate the overall response rate (ORR) of apalutamide in combination with a gonadotropin-releasing hormone (GnRH) agonist in participants with androgen receptor (AR) expressing locally advanced or…
- Trial name
- YATAGARASU (NCT04325828)
- Testing
- Apalutamide, GnRH Agonist
- Where
- 7 sites in Japan
- Volunteers
- 31 people
- Sponsor
- Janssen Pharmaceutical K.K.
Oral Leukoplakia
Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia
This is a Phase IIa oral cavity leukoplakia study of pioglitazone 15mg and metformin 500mg BID for 12 weeks. The primary objective is to determine the clinical and histologic changes of leukoplakia from baseline following a 12…
- Trial name
- NCT05727761
- Testing
- pioglitazone-metformin
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- University of Minnesota
Tongue Neoplasms, Tongue Cancer
Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue
This study will fill a scientific gap in the current knowledge providing data for evaluation of the palatal augmentation prosthesis (PAP) as a therapeutic modality post-surgery.
- Conditions
- Tongue Neoplasms, Tongue Cancer, Oral Cancer
- Trial name
- PGSRT (NCT02584270)
- Testing
- Palatal Augmentation Prosthesis (PAP), Articulation Therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Combination Study of Antibiotics With Enzalutamide (PROMIZE)
PROMIZE is an open-label, multi-centre, single-arm, Phase I/II clinical trial, evaluating the safety, tolerability and anti-tumuor efficacy of an antibiotic combination and enzalutamide in patients with metastatic…
- Trial name
- NCT06126731
- Testing
- Enzalutamide 40mg, Amoxicillin 500mg, Metronidazole 400mg
- Where
- 2 sites in Switzerland, United Kingdom
- Volunteers
- 39 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Oral Mucositis, Chemotherapy-induced Oral Mucositis
Ozone Therapy With Biomimetic Oral Care for Cancer-Related Oral Mucositis
Oral mucositis is a frequent and often debilitating complication of radiotherapy and chemotherapy, particularly in patients treated for head and neck cancers.
- Conditions
- Oral Mucositis, Chemotherapy-induced Oral Mucositis, Head and Neck Neoplasms
- Trial name
- OZOMUC (NCT07491536)
- Testing
- Gas Ozone Therapy, Biomimetic Oral Care Regimen
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Pavia
Bladder Cancer, Recurrent Bladder Cancer
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer
The purpose of this study is to assess the effectiveness of erdafitinib in people with non-muscle invasive bladder cancer (NMIBC) that has come back after standard treatment, such as Bacillus Calmette-Guerin (BCG) or chemotherapy…
- Conditions
- Bladder Cancer, Recurrent Bladder Cancer, FGFR3 Gene Mutation
- Trial name
- NCT04917809
- Testing
- Erdafitinib
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Salivary Gland Cancer, HER2 Gene Mutation
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
This research is being done to see how safe and effective the use of the study drug Ado-trastuzumab (T) emtansine (DM1), T-DM1, and standard of care chemoradiation are when used together in treating HER2-positive salivary gland…
- Trial name
- NCT04620187
- Testing
- Ado-trastuzumab (T) emtansine (T-DM1), Standard of Care Radiotherapy, Standard of Care Chemotherapy
- Where
- 13 sites in United States
- Volunteers
- 37 people
- Sponsor
- Dana-Farber Cancer Institute
Anxiety, Pain
Music and VR Effects on Pain, Anxiety, and Fear During Oral Mucositis Care in Leukaemic Children
Children undergoing leukaemia treatment are exposed to a wide range of chemotherapeutic agents and immunosuppressive therapies during treatment and are therefore at great risk for complications.
- Conditions
- Anxiety, Pain, Fear
- Trial name
- NCT06955338
- Testing
- Music intervention, Virtual reality
- Where
- Turkey (Türkiye)
- Volunteers
- 45 people
- Sponsor
- Ege University
Head and Neck Cancer
Impact of the Oral Microbiota on Relapse in HNSCC Patients
to characterise the impact of microbiota in radiotherapy efficacy
- Trial name
- MICR-ORL (NCT06807034)
- Testing
- buccal swabs
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Institut Sainte Catherine
Breast Cancer
A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer
This is a Phase 1/2 dose escalation and cohort expansion study and will assess the safety, tolerability and preliminary efficacy of HP568 alone and in combination with palbociclib in patients with ER+/HER2- locally advanced or…
- Trial name
- NCT06757335
- Testing
- HP568, HP568 in combination with palbociclib
- Volunteers
- 204 people
- Sponsor
- Hinova Pharmaceuticals Inc.
Breast Cancer
AKY15-HK-301_NEPA Study
Nausea and vomiting (feeling sick to your stomach and throwing up) are two of the most common unpleasant side effects of chemotherapy agents (drugs specifically used to treat cancer) that will be used for cancer treatment.
- Trial name
- NCT03386617
- Testing
- NEPA
- Where
- Hong Kong
- Volunteers
- 55 people
- Sponsor
- Chinese University of Hong Kong
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia
Non-commercial, open-label interventional phase Ib study to assess the effectivity of the combination of venetoclax and 6-mercaptopurine in patients with relapsed or refractory AML.
- Trial name
- NCT05506332
- Testing
- Venetoclax, 6-mercaptopurine
- Where
- 2 sites in Belgium
- Volunteers
- 10 people
- Sponsor
- University Hospital, Antwerp
Muscle Loss
Branched Chained Amino Acid Supplement in Patients Undergoing Lower Limb Bone Cancer Curettage for Bone Metastasis
Postoperative muscle loss is common in patients with bone metastases undergoing lower limb bone cancer curettage, affecting both limb skeletal muscles and potentially swallowing-related muscles.
- Trial name
- NCT06604910
- Testing
- branched chained amino acid
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Cancer Head Neck
Single and Combined Modality Trans-Oral Robotic Surgery in Early Oropharyngeal Cancer
Multi-centre retrospective observational cohort study with optional exploratory radiomic study (international) and prospective molecular analysis studies (UK only).
- Trial name
- SCORE (NCT05933889)
- Testing
- Molecular Analysis, Radiomic/ Morphological analysis
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Solid Tumours
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine
This study is open to adults with solid tumours who received at least 4 cycles of treatment with brigimadlin in a previous study.
- Trial name
- NCT06619509
- Testing
- Brigimadlin
- Where
- 50 sites in United States, Argentina and 18 more
- Volunteers
- 90 people
- Sponsor
- Boehringer Ingelheim
Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
This phase III trial compares the safety and effect of adding vinorelbine to vincristine, dactinomycin, and cyclophosphamide (VAC) for the treatment of patients with high risk rhabdomyosarcoma (RMS).
- Conditions
- Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma, Metastatic Embryonal Rhabdomyosarcoma
- Trial name
- NCT04994132
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 250 sites in United States, Australia and 3 more
- Volunteers
- 113 people
- Sponsor
- Children's Oncology Group
Advanced Solid Tumors, Metastatic Pancreatic Cancer
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Background: Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or reduces metastasis. Researchers hope a new drug can help.
- Conditions
- Advanced Solid Tumors, Metastatic Pancreatic Cancer, Pediatric Solid Tumor, Advanced Breast Cancer
- Trial name
- NCT04222413
- Testing
- Metarrestin
- Where
- 2 sites in United States
- Volunteers
- 116 people
- Sponsor
- National Cancer Institute (NCI)
Oral Cavity Cancer, Dysphagia
Dysphagia and Quality of Life in Patients With Oral Squamous Cell Carcinoma Before and After Treatment
While the group of oral cavity cancer (OCC) survivors continue to increase, surgeons and oncologist intensify their search for improved treatment and rehabilitation methods to reduce the morbidity of management without…
- Conditions
- Oral Cavity Cancer, Dysphagia, Quality of Life
- Trial name
- NCT06407570
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- University of Aarhus
Advanced Non-small Cell Lung Cancer, HER2 Mutation
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations.
- Trial name
- SOHO-02 (NCT06452277)
- Testing
- Sevabertinib, Pembrolizumab, Cisplatin
- Where
- 279 sites in United States, Argentina and 34 more
- Volunteers
- 444 people
- Sponsor
- Bayer
Head and Neck Cncer
Oral Health-Related Quality of Life Using EORTC QLQ-H&N35 in Head and Neck Cancer Survivors Within the First Year Following Treatment: a Cross-Sectional Study in Egypt
This study aims to evaluate Oral Health-Related Quality of Life (OHRQoL) in head and neck cancer (HNC) survivors within the first year following treatment in Egypt.
- Trial name
- NCT06901401
- Where
- Egypt
- Volunteers
- 112 people
- Sponsor
- Ain Shams University